1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Down Syndrome - Pipeline Review, H1 2017

Down Syndrome - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 65 pages

Down Syndrome - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome – Pipeline Review, H1 2017, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape.

Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays and other problems. Down syndrome varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short neck, protruding tongue, upward slanting eyes, unusual for the child's ethnic group and unusually shaped ears. Children with Down syndrome may also have poor muscle tone, broad, short hands with a single crease in the palm, relatively short fingers and excessive flexibility.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Down Syndrome – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Down Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Down Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Down Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Down Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Down Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Down Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Down Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Down Syndrome (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Down Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Down Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Down Syndrome - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Down Syndrome - Overview
Down Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Down Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Down Syndrome - Companies Involved in Therapeutics Development
AC Immune SA
Aelis Farma SAS
Cortice Biosciences Inc
Eisai Co Ltd
ManRos Therapeutics
NeuroNascent Inc
OPKO Health Inc
Down Syndrome - Drug Profiles
ACI-24 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ALZ-801 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
APH-1104 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
D-217 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
donepezil hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Dosmir - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ELND-005 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
minocycline hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NNI-351 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NNI-362 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pentylenetetrazol - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule to inhibit DYRK1A for Alzheimer's and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules for Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Stem Cell Therapy to Activate ZSCAN4 for Down Syndrome, Dyskeratosis Congenita and Edwards Syndrome - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
xamoterol fumarate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Down Syndrome - Discontinued Products
Down Syndrome - Product Development Milestones
Featured News and Press Releases
Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome
Aug 31, 2015: New Down syndrome therapy discovered
Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics
Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome
Apr 07, 2014: Transition Therapeutics Announces Development Update
Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome
Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Down Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Down Syndrome - Pipeline by AC Immune SA, H1 2017
Down Syndrome - Pipeline by Aelis Farma SAS, H1 2017
Down Syndrome - Pipeline by Cortice Biosciences Inc, H1 2017
Down Syndrome - Pipeline by Eisai Co Ltd, H1 2017
Down Syndrome - Pipeline by ManRos Therapeutics, H1 2017
Down Syndrome - Pipeline by NeuroNascent Inc, H1 2017
Down Syndrome - Pipeline by OPKO Health Inc, H1 2017
Down Syndrome - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Down Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016’, provides in depth ...

TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016

TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016’, provides in depth ...

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2016

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Alpha Synuclein (Non A Beta ...

Stroke - Pipeline Review, H2 2016

November 2016 $ 2000

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.